(Q34456258)

2 August 2017

1 reference

title

The role and utility of faecal markers in inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

2 August 2017

0 references

0 references

author name string

Frank S Lehmann

series ordinal

1

1 reference

2 August 2017

Emanuel Burri

series ordinal

2

1 reference

2 August 2017

Christoph Beglinger

series ordinal

3

1 reference

2 August 2017

publication date

1 January 2015

1 reference

Therapeutic Advances in Gastroenterology

2 August 2017

published in

1 reference

2 August 2017

volume

8

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

23-36

1 reference

Clinical and histopathological correlations of fecal calprotectin release in colorectal carcinoma

2 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Optimising monitoring in the management of Crohn's disease: a physician's perspective

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Faecal calprotectin -- a useful tool in the management of inflammatory bowel disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Clinical implications of mucosal healing for the management of IBD.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Fecal lactoferrin: a new parameter to monitor infliximab therapy.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Role of faecal calprotectin as non-invasive marker of intestinal inflammation.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

A simple method for assessing intestinal inflammation in Crohn's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Predictability of the postoperative course of Crohn's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Fecal MMP-9: a new noninvasive differential diagnostic and activity marker in ulcerative colitis

6 July 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

Fecal excretion of deoxyribonucleic acid in long-term follow-up of patients with inactive ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

Faecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

Rapid test for fecal calprotectin levels in children with Crohn disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

The assessment of a rapid noninvasive immunochromatographic assay test for fecal lactoferrin in patients with suspected inflammation of the ileal pouch.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

Fecal calprotectin mirrors inflammation of the distal ileum and bowel function after restorative proctocolectomy for pediatric-onset ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

Faecal lactoferrin--a novel test to differentiate between the irritable and inflamed bowel?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

Faecal calprotectin in children with clinically quiescent inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

Subclinical intestinal inflammation: an inherited abnormality in Crohn’s disease relatives?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

Evaluation of the Quantum Blue® rapid test for faecal calprotectin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265086

Diagnostic Accuracy of Point-of-Care Fecal Calprotectin and Immunochemical Occult Blood Tests for Diagnosis of Organic Bowel Disease in Primary Care: The Cost-Effectiveness of a Decision Rule for Abdominal Complaints in Primary Care (CEDAR) Study

27 October 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

Limitations of Fecal Calprotectin At Diagnosis in Untreated Pediatric Crohnʼs Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X14553384

Matrix metalloproteinase levels are elevated in inflammatory bowel disease

21 January 2018

1 reference

12 December 2020

Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study

1 reference

12 December 2020

Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease

1 reference

12 December 2020

The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound

1 reference

12 December 2020

Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis

1 reference

12 December 2020

Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm

1 reference

12 December 2020

Faecal calprotectin in children with chronic gastrointestinal symptoms

1 reference

12 December 2020

Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers

1 reference

12 December 2020

Safely ruling out inflammatory bowel disease in children and teenagers without referral for endoscopy

1 reference

12 December 2020

Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI

1 reference

12 December 2020

Assessment of ileal pouch inflammation by single-stool calprotectin assay

1 reference

12 December 2020

Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies

1 reference

12 December 2020

Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices

1 reference

12 December 2020

Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy

1 reference

12 December 2020

Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease

1 reference

12 December 2020

Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin

1 reference

12 December 2020

Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases

1 reference

12 December 2020

Fecal calprotectin variability in Crohn's disease

1 reference

12 December 2020

A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells

1 reference

12 December 2020

Fecal S100A12: a novel noninvasive marker in children with Crohn's disease

1 reference

12 December 2020

Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease

1 reference

12 December 2020

Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation

1 reference

12 December 2020

Faecal calprotectin in the assessment of Crohn's disease activity

1 reference

12 December 2020

Fecal calprotectin is equally sensitive in Crohn's disease affecting the small bowel and colon

1 reference

12 December 2020

Immunochemical detection of human lactoferrin in feces as a new marker for inflammatory gastrointestinal disorders and colon cancer

1 reference

12 December 2020

Diagnostic work-up of inflammatory bowel disease in children: the role of calprotectin assay

1 reference

12 December 2020

Fecal calprotectin, MMP-9, and human beta-defensin-2 levels in pediatric inflammatory bowel disease

1 reference

12 December 2020

Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease

1 reference

12 December 2020

Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?

1 reference

12 December 2020

Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease

1 reference

12 December 2020

Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease

1 reference

12 December 2020

Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease

1 reference

12 December 2020

Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease

1 reference

12 December 2020

The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease

1 reference

12 December 2020

Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease

1 reference

12 December 2020

Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome

1 reference

12 December 2020

Relationship between fecal lactoferrin and inflammatory bowel disease

1 reference

12 December 2020

The correlation between fecal calprotectin, simple clinical colitis activity index and biochemical markers in ulcerative colitis during high-dose steroid treatment

1 reference

12 December 2020

Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms

1 reference

12 December 2020

Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein

1 reference

12 December 2020

Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents

1 reference

12 December 2020

Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease

1 reference

12 December 2020

Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology

1 reference

12 December 2020

Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation

1 reference

12 December 2020

Fecal lactoferrin, myeloperoxidase and serum C-reactive are effective biomarkers in the assessment of disease activity and severity in patients with idiopathic ulcerative colitis

1 reference

12 December 2020

Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease

1 reference

12 December 2020

Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children

1 reference

12 December 2020

Accuracy of four fecal assays in the diagnosis of colitis

1 reference

12 December 2020

Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation

1 reference

12 December 2020

Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn's disease

1 reference

12 December 2020

Can calprotectin predict relapse risk in inflammatory bowel disease?

1 reference

12 December 2020

Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease

1 reference

12 December 2020

Identifiers

DOI

10.1177/1756283X14553384

1 reference

2 August 2017

1 reference

2 August 2017

1 reference